Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer

NCT04857697 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04857697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04857697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2021
Completion date
March 8, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, breast adenocarcinoma, stage i lung cancer ajcc v8, stage ii lung cancer ajcc v8, stage iii lung cancer ajcc v8